The financing will allow FlexGen to speed up the development and global commercialization of its FlexArrayer, an instrument that provides researchers with unprecedented freedom in the production of custom microarrays.
FlexGen is collaborating with several scientific and industrial customers and partners to develop innovative solutions for next generation sequencing, biomarker validation and other application areas.
Fred Dom, CEO of FlexGen, said: “We are very pleased to have two investors on board that give us the opportunity to bring the company to the next level. The rapidly growing use of next generation sequencing has created exciting opportunities for FlexGen.
“With the support of our new investors we are able to take a strong position in this growing market; the FlexArrayer provides the customer fast and flexible tools for genomic selection and biomarker validation that can easily be integrated in the high throughput approaches that sequencing facilities require.”